Balchem Corporation (BCPC)
Official siteBASIC MATERIALS • SPECIALTY CHEMICALS • NASDAQ
Market Cap: $5.52B
Last updated: Nov 17, 2026 at 11:04 AM ET
Balchem Corporation (BCPC) Stock Forecast
Analysts expect Balchem (BCPC) to earn $5.87 per share in the fiscal year ending Dec 31, 2026, on revenue of $1.13B. Of 3 analysts, 2 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 3 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 67% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 33.3% |
| Buy | 1 | 33.3% |
| Hold | 1 | 33.3% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 3
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 8.3% and revenue estimates rise 6.2%.
- Fiscal year ending Dec 31, 2026
- $5.87
- EPS consensus, revenue $1.13B
- Fiscal year ending Dec 31, 2027
- $6.36
- EPS consensus, revenue $1.20B
- Next report
- Feb 18, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $5.87 | $5.85 to $5.91 | 3 | $1.13B | $1.12B to $1.14B | 4 |
| Dec 31, 2027 | $6.36 | $6.20 to $6.64 | 3 | $1.20B | $1.17B to $1.22B | 4 |
Quarterly Estimates
The EPS consensus falls from $1.49 for the quarter ending Dec 31, 2026 to $1.48 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $1.49 | $1.43 to $1.54 | 5 | $292.65M | $273.32M to $312.06M | 5 |
| Mar 31, 2027 | $1.48 | $1.47 to $1.48 | 2 | $284.61M | $280.10M to $288.24M | 3 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 5 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 2 | 0 |
| Fiscal year ending Dec 31, 2027 | 2 | 0 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 0.7% from $5.83.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $5.87 | $5.87 | $5.84 | $5.84 | $5.83 | +0.8% |
| Fiscal year ending Dec 31, 2027 | $6.36 | $6.27 | $6.27 | $6.27 | $6.21 | +2.5% |
| Quarter ending Mar 31, 2027 | $1.48 | $1.43 | $1.43 | $1.43 | $1.44 | +2.4% |
Frequently Asked Questions About BCPC
What is the BCPC stock forecast?
Consensus analyst estimates put Balchem's EPS at $5.87 for the fiscal year ending Dec 31, 2026, on revenue of $1.13B. The consensus rating from 3 analysts is Buy.
How do analysts rate BCPC stock?
Of 3 analysts covering Balchem, 1 rates it Strong Buy, 1 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from BCPC next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $5.87, with estimates from $5.85 to $5.91 from 3 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $6.36, with estimates from $6.20 to $6.64 from 3 analysts.
What revenue do analysts expect from Balchem next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $1.13B, with estimates from $1.12B to $1.14B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $1.20B, with estimates from $1.17B to $1.22B.
How many analysts cover BCPC?
3 analysts rate Balchem stock, and 3 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
BCPC pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors